Dermavant products. Dermavant to Present New Data from the Phase 3 PSOARING 3 Long-Term Extension Trial of Tapinarof Cream for Adults with Plaque Psoriasis at the 2022 American Academy of Dermatology. Dermavant products

Exhibit 10. & BASEL, Switzerland, November 08, 2022--Dermavant Announces Highly Favorable Results from Pediatric Maximal Usage Study of VTAMA® (tapinarof) cream, 1% in Atopic DermatitisDermavant Sciences GmbH: ClinicalTrials. [email protected]. Release Summary. This trademark is owned by Dermavant Sciences GmbH. Micro 255, UNC. The fifth NDA submission to FDA: Dermavant's once-daily, steroid-free and cosmetically elegant topical cream tapinarof for the treatment of mild, moderate and severe plaque psoriasis in adult patientsAdvancing Innovation in Dermatology, Inc. c. Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old; Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% Once. All products from Dermavant brand with ingredients rated for skin health and safety. A Passion for Science and a Commitment to Dermatology | A Passion for Science and a Commitment to Dermatology Dermavant Sciences is a specialty biopharmaceutical company developing innovative prescription therapies for dermatologic diseases. and thereby provide differentiation from other products on the market. confidential . is a clinical-stage biopharmaceutical company developing new medical dermatology products to treat psoriasis, atopic dermatitis, vitiligo, primary focal hyperhidrosis, and. Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. , and BASEL, Switzerland, March 11, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in. 6 million children have AD. Dermavant is also developing VTAMA for the treatment of atopic dermatitis in adults and children and released positive. Under the agreement, GSK will receive an upfront payment of £150m followed by £100m potential milestone-based payments in the future. Roivant group company Dermavant has made the transition to a commercial-stage company after getting FDA approval for Vtama, a drug for psoriasis that it claims could be a game-changer in the. Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old; Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% Once. Dermavant is also developing VTAMA cream, 1% for the treatment of atopic dermatitis in adults and children and released topline results from its Phase 3 clinical trial, ADORING 2, in March 2023. Apr 2014. Dermavant is also developing VTAMA cream, 1% for the treatment of atopic dermatitis in adults and children and expects to release topline results from its Phase 3 clinical trials in the first half. BASEL, Switzerland, July 10, 2017 /PRNewswire/ — Dermavant Sciences, a biopharmaceutical company dedicated to developing and commercializing innovative therapies in medical dermatology, today announced the appointment of Dr. Dermavant is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno. has determined the information (i) is not material and (ii) would likely cause competitive harm to dermavant sciences ltd. From 2005 to 2013, Mr. Dermavant Announces Tapinarof Data Presentation at the Innovations in Dermatology Conference. There are currently no FDA approved topical Jak/SYK inhibitors for the treatment of atopic dermatitis (AD). Managed 3 core products (Lumigan, Combigan, and Alphagan) in the glaucoma disease state, through strategic sales and marketing, to drive revenue and growth. $89. Dermavant Sciences Ltd. Monday – Friday | 8am- 8pm ET. 18% and 0. Dermavant is dedicated to realizing the full potential of biomedical research and to developing and commercializing novel, first-in-class or best-in-class therapies that. Jacqualyn “Jackie” Fouse as Executive Chairman. Dermavant: Dermavant expects a decision from the FDA on the approval of tapinarof for the treatment of adults with plaque psoriasis in the second quarter of calendar year 2022. 5. Recent Posts. LONG BEACH, Calif. We are passionate and dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in-class therapies that. 4%, representing 0. S. 37% of free base,. Dermavant’s focus is to develop therapies that have the potential to address high unmet medical needs while driving greater efficiency in. $49. & BASEL, Switzerland, November 22, 2022--Dermavant Launches First Commercial for VTAMA® (tapinarof) cream, 1% as Part of a National, Multimedia Campaign for Adults with Plaque. Dermavant labs, USA. Cerdulatinib (DMVT-502) is an investigational kinase inhibitor with demonstrated activity against Jak and SYK (Coffey et al. 03 Apr, 2018, 07:00 ET. Dermavant Announces Tapinarof Data Presentation at Maui Derm for Dermatologists 2021. The federal status of this trademark filing is REGISTERED as of Tuesday, January 25, 2022. Roivant is a pharmaceutical company with a unique business model of strategically acquiring businesses and pipeline products from other companies. View All ProductsDermavant to Present Data from Multiple Studies of VTAMA® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting. Order Now: 1-800-511-4356Find irritant free beauty, skincare & household products that are free of ingredients like retinol/retinal, glycolic acid, alpha hydroxy acids, benzoyl peroxide and peeling or. Observers will be. Dermavant’s pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study. gov. National Library of Medicine: ClinicalTrials. Dermavant is dedicated to the research, development and commercialization of products for the treatment of certain human diseases, disorders, and conditions. MEDIK8 NGDC. About Dermavant’s Phase 3 Program for Tapinarof in Psoriasis. execution version . gov/medwatch or call 1-800-FDA-1088 or report side effects to Dermavant Sciences at 1-8 DERMAVANT (1-833-762-8268). Mr. The USPTO has given the VTAMA trademark a serial number of 90401654. Dermavant to Present Data from Multiple Studies of VTAMA ® (tapinarof) cream, 1% at the 2023 American Academy of Dermatology Annual Meeting Dermavant Completes Enrollment of Two Phase 3 Clinical Trials of VTAMA ® (tapinarof) cream, 1% for the treatment of Atopic Dermatitis in Adults and Children as Young as 2 years old– Dermavant to Receive $160 Million from Revenue Interest Sale Upon FDA Approval of Tapinarof, Participants Include Marathon Asset Management and NovaQuest Capital Management –. S. Dermavant Sciences | 19. by and among . Eisai. Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company committed to fostering unprecedented change and unparalleled impact in immuno-dermatology. Nelson served as the President. About atopic dermatitis. com. Territory Sales Manager Warner ChilcottApply for a Dermavant Territory Business Manager (Phoenix) job in Phoenix, AZ. Our Products. Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old; Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% Once. Bryan. Recent Posts. The Field Medical Director engages in scientific exchange with medical and scientific experts, including Healthcare Professionals and Managed. Dermavant Sciences has announced that the U. About Dermavant’s Phase 3 Program for Tapinarof in Psoriasis. Dermavant’s pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a. asset purchase agreement . , and BASEL, Switzerland, January 21, 2021—Dermavant Sciences, a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno. in 25 Years - EFFICACY: In the pivotal Phase 3 clinical trial program, VTAMA cream met all primary and secondary endpoints and demonstrated highly. This number represents the median, which is the midpoint of the ranges from our proprietary Total Pay Estimate model and based on salaries collected from our users. About Dermavant: Dermavant Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory skin diseases and medical dermatologic conditions. To ensure compliance with the laws, industry guidelines, and Dermavant standards applicable to the development, manufacturing, marketing, and sale of our products, the Company has established a Comprehensive Compliance Program (CCP) that is consistent with the Department of Health and Human Services Office of Inspector General Guidance. Prurituse 20 (3) 2 (1) Influenzaf 14 (2) 2 (1) a Folliculitis includes application site folliculitis and folliculitis b Nasopharyngitis includes nasopharyngitis, nasal congestion, pharyngitis, respiratory tract infection (RTI) viral, rhinorrhea, sinus congestion, upper RTI, and viral upper RTI . Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. if publicly disclosed. About Dermavant: Dermavant Sciences is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory skin diseases and medical dermatologic conditions. (the “Company”). Beesley has helped launch more than 70 products within disease spaces such as ophthalmology, wound care, rare disease, neurology, aesthetics. Timothy S. Additional experience spans from large pharmaceutical to small venture-funded device. GlaxoSmithKline ( GSK) has signed an agreement to divest rights to tapinarof, one of its investigational drugs, to Dermavant Sciences, a division of Roivant Sciences, following a deal valued at £250m. EMPLOYMENT AGREEMENT. Use the CB Insights Platform to explore Dermavant's full profile. Recent Posts. LONG BEACH, Calif. Recent Posts. Spectrafilm 12*14. , which are both private biopharmaceutical companies. Nelson currently serves on the board of directors of Impel NeuroPharma, Inc. 5 million adults and 9. Each gram of Vtama Cream for topical use contains 10 mg of tapinarof in a white to off-white cream. Blueprint keeps co-founder Alexis Borisy as director—without majority. Beesley Brings Over 25 Years’ Experience Launching New Therapeutics. At Dermavant Sciences, we are committed to fostering unprecedented change and unparalleled impact in immuno-dermatology by rethinking the entire patient journey. We are passionate and dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in. dna Communications: Angela Salerno-Robin. Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Consumer Products companies today have a wealth of information, capabilities, knowledge and technology to generate demand forecasts. Dermavant currently has three investigational drugs in. if publicly disclosed. Recent Posts. See full Prescribing Information and Patient Information at VTAMA. The FDA has approved tapinarof 1% cream (Vtama; Dermavant Sciences) for the topical treatment of plaque psoriasis in adults. 95. Dermavant Sciences is a clinical-stage biopharmaceutical company committed to developing innovative therapeutics in immuno-dermatology. A Senior Pharmaceutical professional with over 20 years of technical experience and leadership in Pharmaceutical Organizations, leading formulation, process, and analytical development, across a. Dileep seeks to understand - and connect with - the customer. By entering my email I agree to allow Dermavant Sciences, Inc. Previously, Janine was an Associate Director, Health Ou tcomes National Accounts at Novo Nordisk and also held positions at Diabetes Coalition of California, Kaiser Permanente, Northeastern University,. sponsored and are retrieved from the U. Dermavant has acquired promising. Recent Posts. Our mission is to make healthier skin a reality for the millions of people around the world living with chronic skin conditions. has determined the information (i) is not material and (ii) would likely cause competitive harm to dermavant sciences ltd. LONG BEACH, Calif. Dermavant’s pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study. It is not intended for promotional purposes or to offer medical advice and may contain information about products and/or uses that have not been approved by the US Food. Industry: Biotech & Pharmaceuticals. LONG BEACH, Calif. Atopic dermatitis (AD), commonly referred to as eczema, is a chronic inflammatory skin disease that is characterized by dry, itchy, red, swollen, and/or cracked skin. 4% of subjects receiving VTAMA cream, 1% achieved the primary endpoint of Validated Investigator Global Assessment. With approval supplement on deck, Reata dives into launch of its first commercial product Skyclarys. We are passionate and dedicated to realizing the full potential of biomedical research and to developing and commercializing novel first-in-class or best-in. Develop outstanding disease and product knowledge to compliantly promote Dermavant's products to healthcare professionals;Roivant Sciences, a three-year-old, Basel, Switzerland-based company aiming to one day be a giant holding company for dozens of independent biopharmaceutical companies, has raised $1. Learn more about our products here. 18 matches were found and 10 studies were returned. Apply online instantly. Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old; Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% Once. <br. 1,2 AD is one of the most common inflammatory skin diseases. The mission of the Dermatology Summit is to build a community of people who are excited about innovation in dermatology. Present data and conduct balanced peer-to-peer scientific dialogue on Dermavant products with HCPs, academic institutions, clinical investigators, and other stakeholders that is consistent with. Dermavant shall, and shall ensure that its Affiliates and sublicensees will, maintain adequate records to permit Dermavant to trace the manufacture, distribution and use of the Products. About Dermavant’s Phase 3 Program for Tapinarof in Psoriasis. Dermavant shall have the sole discretion with respect to any matters relating to any Remedial Action with respect to any Product in the Licensed Field in the. Late Stage Products (Phase III) Tapinarof: Dermavant Sciences; Drug profiles in the detailed report…. 95. We produce premium skin care products, including RevitaBright, RevitaGen, RevitaLume and RevitaShape. Our teams are agile, adaptable, and accountable, and our speak-up culture ensures we meet every milestone to help us deliver products that patients and physicians have been waiting for, as quickly as possible. Dermavant Sciences, a subsidiary of Roivant Sciences, is a biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology. Nelson has served as a member of our board of directors since April 2019. ” INTRODUCTION . Dermavant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old; Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% Once. Dermavant’s pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 (NCT03956355) and PSOARING 2 (NCT03983980), as well as PSOARING 3 (NCT04053387), a long-term extension study. Gilmartin: Laurence Watts. Ms. Director, HEOR at Dermavant Sciences. Welcome to Dermavant Sciences This portal is intended as an educational resource for US healthcare professionals to facilitate the scientific exchange of medical information. such as dermatology, aesthetics, wound care, rare disease, ophthalmology, and neurology, helping to launch more than 70 products. Call 1-8-DERMAVANT (1-833-762-8268) for Medical Information, Adverse Event Reporting, or Product Quality Complaints. , a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics in immuno-dermatology, today announced positive results from ADORING 2, one of two double-blind, randomized,. Janine Fournier is a Director, HEOR at Dermavant Sciences based in Long Beach, California. 3 In the US, more than 16. BASEL, Switzerland, April 3, 2018 /PRNewswire/ -- Dermavant Sciences, a biopharmaceutical company focused on developing innovative therapies for dermatologic conditions. GSK, Roivant, and Dermavant also agreed to enter into agreements covering tapinarof’s Phase III program and commercial supply. Complaint Reporting. Contact dermatitis includes dermatitis, contact dermatitis, hand dermatitis, and rashPresent data and conduct balanced peer-to-peer scientific dialogue on Dermavant products with HCPs, academic institutions, clinical investigators, and other stakeholders that is consistent with. Dermavant Announces Tapinarof Data Presentations at the AAD VMX 2021. com. Maximum day supply limit may vary. dated august 20, 2018. The Field Medical Director is a field-based professional with scientific, clinical and therapeutic area expertise responsible for providing medical and scientific support for Dermavant’s programs. Share. Dermavant’s pivotal Phase 3 clinical program for tapinarof in adult plaque psoriasis consists of PSOARING 1 and PSOARING 2, plus a long-term safety study. improve our products and services, and identify, develop, and offer new or expanded products and services; personalize your experience on this Website, and customize the content and/or format of the pages you visit; notify you about updates, products, services, and/or special offers from Dermavant Sciences, its affiliates, and selected third. Dermavant is prepared for a June 2022 launch with product and sample manufacturing runs completed and a fully staffed commercial team. This Employment Agreement (this “Agreement”) is entered into as of October 27, 2018, by and between Todd Zavodnick (the “Executive”) and Dermavant Sciences, Inc. Dermavant: We expect a decision from the FDA on the approval of tapinarof for the treatment of adults with plaque psoriasis in the second calendar quarter of 2022. About Dermavant’s Phase 3 Program for Tapinarof in Psoriasis. Execution Version . That’s why we’re hard at work. Dermavant. LONG BEACH, Calif. The article Dermavant Sciences officially withdraws $100 million IPO. 32, and the following structural formula. Its pipeline targets specific unmet needs in two of the growing immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary. and is Chairman of the Board of XOC Pharmaceuticals, Inc. Dermavant Reports Positive Topline Results from ADORING 2 Atopic Dermatitis Phase 3 Trial of VTAMA ® (tapinarof) Cream, 1% Once Daily in Adults and Children as Young as 2 Years Old – 46. Dermavant also completed a strategic pipeline review and has terminated the development of DMVT-502 for vitiligo and atopic dermatitis, DMVT-503 for acne and DMVT-504 for hyperhidrosis to focus on the potential blockbuster launch of VTAMA for plaque psoriasis and execution of the Phase 3 clinical trials of VTAMA for atopic. Food and Drug Administration (FDA) approved VTAMA (tapinarof) cream, 1%, indicated for the topical treatment of plaque psoriasis in adults. FDA Approves Dermavant's VTAMA ® (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U. Exhibit 10. Fierce Pharma.